drugset

drugset / Trial / NCT04701788

A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the Elderly

NCT04701788 ↗

Phase 4 Completed 331 enrolled China National Biotec Group Company Limited Sichuan Center for Disease Control and Prevention · collab

Non-randomizedParallel-groupOpen-labelPrevention

Summary

To evaluate the the immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly

Timeline

Start: 2021-03-30
Primary completion: 2021-12-20
Completion: 2022-02-15

Publications

Qiu J, Li Z, Huang F, Huang Z, Liang X, Li J, Liao Y, Guo X, Sun X. Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60-70 years in Shanghai, China. Front Immunol. 2025 Jul 17;16:1623611. doi: 10.3389/fimmu.2025.1623611. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pneumovax 23	Vaccine	—	Other

Indications

No indication recorded.